SAN DIEGO–(BUSINESS WIRE)–MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new cancer therapies, today announced that Anne Frese, an experienced industry executive, joined MEI as Director of Human Resources, a role reporting to Daniel P. Gold, Managing Director. Ms. Frese will be responsible for the strategy and processes related to building and retaining an exceptional team of professionals. Ms. Frese’s appointment is effective immediately.
Ms. Frese joins MEI with over 30 years of human resources experience in a variety of industries, including biotechnology, consulting, hospitality and engineering. Most recently, she served as Director of Human Resources at Vyripharm Enterprises. Previously, Ms. Frese’s experience includes serving as Vice President of Human Resources at Artiva Therapeutics and Bellicum Pharmaceuticals, Inc. She earned a bachelor’s degree in labor relations and economics from McGill University.
“Anne is a highly experienced and capable leader with a knack for building high performing organizations and teams,” said Dan Gold, Managing Director of MEI Pharma. “In her new role, Anne will support the development of our teams, processes and operations based on her passion for people. On behalf of our management team, I welcome Anne and look forward to working with her.
“I am delighted to join MEI and look forward to supporting the continued growth of the organization. MEI’s leadership team is deeply committed to fostering a culture of collaboration, in which the team is bound by a mission to make a meaningful impact in the lives of patients,” said Ms. Frese.
About MEI Pharma
MEI Pharma, Inc. (Nasdaq: MEIP) is a late-stage pharmaceutical company focused on developing potential new cancer therapies. MEI Pharma’s pipeline of drug candidates contains several clinical-stage assets, including zandelisib, currently in clinical trials that may support marketing approvals from the U.S. Food and Drug Administration and other authorities regulations globally. Each of the candidates in MEI Pharma’s pipeline leverages a different mechanism of action with the goal of developing therapeutic options that are: (1) differentiated, (2) address unmet medical needs, and (3) provide enhanced benefits to patients. patients, either as stand-alone treatments or in combination with other treatment options. For more information, please visit www.meipharma.com. Follow us on twitter @MEI_Pharma and on LinkedIn.
Under US law, a new drug cannot be marketed until it has undergone clinical studies and has been approved by the FDA as safe and effective for its intended use. Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, without limitation , statements regarding: the potential, safety, efficacy, and regulatory and clinical progress of zandelisib and our other product candidates, including the expected timing for clinical trial initiation and publication of clinical trial data and our expectations regarding potential regulatory submissions, approvals and timing thereof, our strategy and business plans; and the adequacy of our cash, cash equivalents and short-term investments to fund our operations. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management’s current expectations and are subject to a number of risks and uncertainties, including, but not limit, our inability to successfully commercialize our product candidates; the availability or desirability of utilizing the FDA’s accelerated approval pathway for our product candidates; final data from our preclinical studies and completed clinical trials may differ materially from interim data reported from ongoing studies and trials; costs and delays in the development and/or FDA approval, or failure to obtain such approval, of our product candidates; uncertainties or differences in the interpretation of clinical trial results; adverse effects on the Company’s business as a result of the restatement of our previously issued financial statements; the impact of the COVID-19 pandemic on our industry and individual businesses, including our counterparties, supply chain, execution of our clinical development programs, access to funding and resource allocation governmental; our inability to maintain or enter into, and risks resulting from our reliance on, collaboration or contractual arrangements necessary for the development, manufacture, merchandising, marketing, sale and distribution of any product; competitive factors; our failure to protect our patents or proprietary rights and to obtain necessary patent and intellectual property rights from third parties to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; failure of any product to achieve market acceptance; our inability to obtain any additional financing required; technological changes; government regulations; changes in industry practices; and occasional events. We do not intend to update these factors or publicly announce the results of any revisions to these forward-looking statements.